Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658658 · ClinicalTrials.gov registry record · Phase 1
Panitumumab in Children With Solid Tumors
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00658658 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 31 participants.
The verdict
NCT00658658, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the safety and pharmacokinetics of up to 3 different dose schedules of panitumumab in pediatric patients with solid tumors.
Interventions
- BIOLOGICAL Panitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658658
The ClinicalTrials.gov registry entry for NCT00658658 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Panitumumab is the first listed.
NCT00658658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658658 about?
NCT00658658 is a clinical study titled "Panitumumab in Children With Solid Tumors". The primary objective of this study was to evaluate the safety and pharmacokinetics of up to 3 different dose schedules of panitumumab in pediatric patients with solid tumors.
What is the current status of trial NCT00658658?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2008-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT00658658?
The interventions under investigation include: Panitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00658658?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.